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Vascular surgery to a large extent depends on the use 
of drugs that influence blood coagulability. Heparin, 
introduced in the 1920s, is widely used by vascular 
surgeons during the perioperative period, but seems 
to have lost some of its popularity probably because its 
long term use is cumbersome. In the late 1970s and 
early 1980s the distal arterial tree has increasingly been 
the target of reconstructive surgery or reopening pro- 
cedures. As a result it became necessary to maintain 
patency over a long period of time by employing phar- 
macological measures. "Old fashioned" drugs, such 
as acetyl-salicylic acid (ASA) have attracted renewed 
interest in the last decade because of their potentially 
beneficial action as platelet stabilising agents. Indeed 
ASA is easy to prescribe and exact postoperative 
patient surveillance isnot necessary, although the best 
dosage regimen i~ a matter of-continuing debate. 
The role of oral anticoagulants, such as coumadin 
and warfarin, has never been fully established and 
other drugs that influence ither blood viscosity or red 
cell deformability ale currently undeF investigation. 
Prostacyclin analogues are interesting not only for 
their vasoactive potential but also because of their 
interaction with the intrinsic clotting system. Finally, 
fibrinolytic agents have attracted considerable interest 
for the treatment of both arterial and venous throm- 
bosis. 
The economic drive of pharmaceutical companies 
plays an important role in the widespread use of 
several drugs that have never been proved to be really 
beneficial in the field of peripheral vascular surgery. 
Controversies exist concerning the type of drugs, the 
value and risk of combinations, dosages, optimal time 
to start treatment and methods of administration. 
Times and fashions change, and a renewed 
interest can currently be noted in the use of oral anti- 
coagulants. Recent discussions at the meeting of the 
American Society for Vascular Surgery and other 
international meetings seem to indicate the redis- 
covery of oral anticoagulants for their possible protec- 
tive action on the short-term and long-term patency of 
femoro-popliteal nd femoro-crural bypasses. 
International attention has been drawn to the 
peculiar and unique situation in the Netherlands, 
where the widespread use of coumadine has been 
possible because of a network of "Thrombosis 
Services", a non-profit organisation to control the in- 
dividual dosage of some 35000 patients with peri- 
pheral arterial disease, with or without vascular 
reconstructions. 
Both in Europe and in the U.S.A. vascular sur- 
geons treat the majority of their patients postoper- 
atively with platelet inhibitors, usually for a period of 
about 1 year. The same can be said for the regimen 
after PTA. However, increasingly and for an obvious 
reason, for the "difficult" and "thrombosis prone" 
(redo) patients, protection with oral anticoagulants is 
seen to be preferable, in spite of a general acceptance 
that the risk of bleeding com:ptications i increased 
with theuse of these drugs. 
At this point it seems reasonable to ask the 
question: What beneficial action of anticoagulant 
drugs has really been proven? And what in fact is the 
risk of haemorrhagic complications associated with 
the use of these drugs? The answers are not easily 
provided. The majority of publications in the 1960s 
and early 1970s on the use of oral anticoagulants in
peripheral vascular disease have one thing in 
common: the studies have no control group or are 
compared with historical controls. 
In 1976 and 1977 three review articles by van 
Vroonhoven and Bruins Slot, 1 Verstraete 2 and Cristol 3 
independently come to the same conclusion: the 
beneficial effect of long-term treatment with oral anti- 
coagulants on the course of peripheral atherosclerotic 
disease--with or without surgical reconstruction-- 
has not been demonstrated; the methodology of all 
previously published studies is unsatisfactory and 
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there is a definite need for prospective randomised 
studies, based on well defined objective criteria and 
study endpoints. 
In 1979 a publication by Schneider et al. 4 seemed 
to fulfil these criteria when they reported a prospective 
randomised series, using oral anticoagulants or anti- 
platelet drugs after TEA or vein-bypass surgery. The 
follow-up period was 2 years and the patient's con- 
dition was evaluated objectively by Doppler pressure 
measurements and patency confirmed by angiogra- 
phy. They came to the surprising conclusion that 
patients with a TEA fared significantly better with 
antiplatelet drugs, whereas patients with a vein- 
bypass procedure did better on oral anticoagulants. 
The authors have no explanation for these peculiar 
results, but make a plea for anticoagulants after by- 
pass surgery and antiplatelet agents after endarterec- 
tomy. 
The American College of Chest Physicians in co- 
operation with the National Heart, Lung and' Blood 
Institute in 1984 started a working group to evaluate 
the indications for, and the efficacy of, treatment with 
anticoagulants and platelet aggregation i hibitors and 
their conclusions were published by Genton et al. in 
1986. 5 They reported that the available data from the 
literature did not provide convincing evidence that 
treatment with antithrombotic agents has a favourable 
influence on the natural history of peripheral athero- 
Sclerotic disease, nor does it prevent or delay arterial 
occlusion after reconstructive ascular surgery. They 
advised against he use of anticoagulants after recon- 
struction in arteries of a diameter of more than 6 mm, 
with a high flow and low resistance. 
Notwithstanding the lack of evidence for a 
beneficial effect, many vascular surgeons have con- 
tinued to treat heir patients with oral anticoagulants, 
either as a routine postoperatively or for "extra safety" 
in high risk patients. 
If benefit has not been proven what are the detri- 
mental effects of oral anticoagulants? Here again, 
there is surprisingly little information i the literature. 
In the few publications where a relationship is noted 
between the level of anticoagulation and positive 
results in peripheral rterial disease, hardly any bleed- 
ing complications are mentioned. Consequently, most 
data on bleeding complications are derived from 
studies on the use of anticoagulants in coronary and 
carotid artery disease. In the Sixty-Plus Reinfarction 
Study Research Group (1982) 6the incidence of intra- 
cranial bleeding is one per 92 treatment years, com- 
pared with one per 67 treatment years in the placebo 
group. Wintzen (1984) calculates, for patients over 50 
years of age and treated with anticoagulants, a ten 
times higher isk of developing an intracranial bleed- 
ing than for individuals of comparable age without 
oral anticoagulants. 7 
Over the years the "art" of anticoagulant treat- 
ment has further developed, the methods of monitor- 
ing coagulation have improved and a trend for 
standardisation can be noted, leading from Quick 
percentages towards an international normalised ratio 
(INR). On the other hand, in the Sixty-Plus Reinfarc- 
tion Study patients were noted to benefit from antico- 
agulant reatment as evidenced by a reduced number 
of ischaemic erebral infarcts, resulting in a lower 
mortality and lless neurological damage. 
A general statement about he risks of anticoagu- 
lant treatment in peripheral arterial disease cannot be 
made. Obviously, the risk largely depends on the 
availability of a system to control the level of antico- 
agulation as frequently as necessary in any individual 
patient, regardless ofwhether the patient is in a hospi- 
tal or at home. Many vascular patients have high 
haematocrit and fibrinogen levels and seem to have a 
less active fibrinolytic system. The final endpoint in 
graft (re)occlusion is thrombosis, o it might be reason- 
able to prescribe anticoagulants. On the other hand, 
vascular patients are often elderly and cannot always 
be relied upon to take drugs regularly. It is generally 
agreed that a strict coagulation control is mandatory to
ensure that the benefits outweigh the risks. When 
these conditions for efficient monitoring of the treat- 
ment are fulfilled the fear of serious bleeding compli- 
cations appears to be somewhat overestimated by 
most authors. 
What is our current position on the use of oral 
anticoagulants? Two important recent studies hould 
be mentioned here. Kretschmer etal. (1986) in Vienna 
performed a prospective trial in patients who received 
a femoropopliteal vein bypass; the patients were ran- 
domly allocated to treatment with oral anticoagulants 
or to no treatment. 8 The results in terms of patency 
rates are similar to the findings of Schneider: 82% 
patency at 18 months for the treatment group and 67% 
for the control group. The difference is significant at a 
p = 0.04 (Breslow) level. In a retrospective study 9by 
the same group (Kretschmer et al., 1988), anticoagu- 
lant treatment also resulted in a significant prolonga- 
tion of life of the patients (n = 668, p = 0.0001). 
The second study ~° is by De Smit (1988) in the 
Netherlands. This author studied the long-term 
follow-up of patients with atherosclerotic disease, 
with and without vascular reconstruction, i  two large 
series: one study (n -- 250) randomising treatment 
with oral anticoagulants v . no treatment, and a 
second study (n = 300) randomising coumadine vs. 
placebo treatment in a double blind fashion. Both 
studies showed definite and very significant (p = 
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0.0001) beneficial effects of long-term anticoagulant 
treatment: progression of atherosclerotic disease was 
significantly diminished as shown by a decreased 
need for further vascular surgical reconstructions, and 
coronary protection was shown, evidenced by a de- 
creased number of myocardial infarctions in the treat- 
ment group. This result is in accordance with the 
results of the Viennese trial, where oral anticoagulants 
seem to prolong postoperative survival. Last, but not 
least, the risk of bleeding complications appears to be 
very moderate, which is even more important because 
a synchronous protection for T.I.A.s and cerebral 
ischaemic infarctions i found. 
So what is the role of oral anticoagulants in peri- 
pheral vascular surgery? The answer regrettably is
that we do not know. Further prospective studies are 
mandatory toconfirm the studies mentioned above. A 
new prospective trial is underway in the Netherlands, 
randomising oral anticoagulants against platelet in- 
hibitors. Naturally, if both drugs have a proven ben- 
eficial effect, and one is not significantly more effective 
than the other, oral anticoagulants have the obvious 
disadvantages of the inconvenience and extra cost of a 
control system. 
Therefore, in conclusion, it can be stated that 
perhaps there is an important role for oral anticoagu- 
lants but this will have to be corroborated by future 
multicentre clinical studies of high quality. Hopefully 
this statement may be an incentive for many European 
colleagues. 
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